• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

原发性CD20阴性弥漫性大B细胞淋巴瘤病例报告

Case report of primary CD20 negative diffuse large B-cell lymphoma.

作者信息

Devi Kanti, Ali Natashi, Ahmed Arsalan

机构信息

Department of Medical Oncology, Aga Khan University, Karachi, Pakistan.

Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.

出版信息

Oxf Med Case Reports. 2021 Nov 25;2021(11):omab114. doi: 10.1093/omcr/omab114. eCollection 2021 Nov.

DOI:10.1093/omcr/omab114
PMID:34858628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8633642/
Abstract

Few groups of aggressive non-Hodgkin's lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentation and this case report is challenging in terms of diagnosis and treatment as well.

摘要

很少有关于对标准化疗难治的侵袭性非霍奇金淋巴瘤（NHL）群体的报道。原发性CD20阴性弥漫性大B细胞淋巴瘤（DLBCL）且无人类免疫缺陷病毒感染是一种不常见的表现，该病例报告在诊断和治疗方面也具有挑战性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdfc/8633642/4584db567012/omab114f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdfc/8633642/6e469c19f259/omab114f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdfc/8633642/4584db567012/omab114f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdfc/8633642/6e469c19f259/omab114f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdfc/8633642/4584db567012/omab114f2.jpg

相似文献

1
Case report of primary CD20 negative diffuse large B-cell lymphoma.原发性CD20阴性弥漫性大B细胞淋巴瘤病例报告
Oxf Med Case Reports. 2021 Nov 25;2021(11):omab114. doi: 10.1093/omcr/omab114. eCollection 2021 Nov.
2
Non-Hodgkin's lymphoma with uncommon clinical manifestations: A case report.具有罕见临床表现的非霍奇金淋巴瘤：一例报告
Oncol Lett. 2015 Sep;10(3):1686-1688. doi: 10.3892/ol.2015.3493. Epub 2015 Jul 15.
3
Follicular lymphoma transforming into anaplastic diffuse large B-cell lymphoma of oral cavity: A case report with review of literature.滤泡性淋巴瘤转化为口腔间变性弥漫性大B细胞淋巴瘤：一例报告并文献复习
J Oral Maxillofac Pathol. 2015 Sep-Dec;19(3):379-84. doi: 10.4103/0973-029X.174617.
4
CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.利妥昔单抗治疗后滤泡性淋巴瘤发生CD20阴性弥漫性大B细胞淋巴瘤转化：一例新病例报告及文献复习
Ann Hematol. 2003 Sep;82(9):585-8. doi: 10.1007/s00277-003-0694-1. Epub 2003 Jul 31.
5
Primary bone lymphomas-Clinical cases and review of literature.原发性骨淋巴瘤——临床病例及文献综述
J Bone Oncol. 2013 Jul 31;2(3):132-6. doi: 10.1016/j.jbo.2013.07.003. eCollection 2013 Sep.
6
De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.新发不可分类的CD20阴性弥漫性大B细胞淋巴瘤：诊断与治疗挑战
Int J Surg Pathol. 2018 May;26(3):266-270. doi: 10.1177/1066896917735170. Epub 2017 Oct 5.
7
Primary Diffuse Large B-Cell Non-Hodgkin's Lymphoma of the Thoracic Spine Presented Initially as an Epigastric Pain.胸椎原发性弥漫性大B细胞非霍奇金淋巴瘤最初表现为上腹部疼痛。
Asian J Neurosurg. 2020 Feb 25;15(1):162-164. doi: 10.4103/ajns.AJNS_300_19. eCollection 2020 Jan-Mar.
8
The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.霍奇金淋巴瘤与非霍奇金淋巴瘤之间的相互关系。
Ann Oncol. 1994;5 Suppl 1:7-11. doi: 10.1093/annonc/5.suppl_1.s7.
9
Hydrocephalus as the sole presentation of primary diffuse large B-cell lymphoma of the brain: Report of a case and review of literature.脑积水作为原发性脑弥漫性大B细胞淋巴瘤的唯一表现：一例报告及文献复习
Surg Neurol Int. 2017 Aug 1;8:165. doi: 10.4103/sni.sni_446_16. eCollection 2017.
10
The therapeutic use of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的治疗应用。
Eur J Haematol Suppl. 2007 Jan(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.

引用本文的文献

1
Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual and Gene Rearrangement: A Diagnostic Challenge.原发性淋巴结不可分类的CD20阴性弥漫性大B细胞淋巴瘤伴双基因重排：一项诊断挑战。
Clin Pathol. 2023 Jan 15;16:2632010X221149978. doi: 10.1177/2632010X221149978. eCollection 2023 Jan-Dec.
2
BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report.布鲁顿酪氨酸激酶抑制剂联合抗程序性死亡蛋白1单克隆抗体治疗CD20阴性原发性中枢神经系统淋巴瘤：一例报告
Oncol Lett. 2022 Dec 15;25(2):48. doi: 10.3892/ol.2022.13634. eCollection 2023 Feb.

本文引用的文献

1
Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.大B细胞淋巴瘤CD20阴性变体患者的生存情况：一项基于国家癌症数据库的分析
Leuk Lymphoma. 2018 Jun;59(6):1375-1383. doi: 10.1080/10428194.2017.1387912. Epub 2017 Oct 11.
2
An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers.一例罕见的缺乏多种B细胞标志物的EB病毒阳性大B细胞淋巴瘤病例。
Diagn Pathol. 2017 Jan 31;12(1):15. doi: 10.1186/s13000-017-0606-7.
3
SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma.
SOX11 是 cyclin D1 阴性套细胞淋巴瘤的一个生物标志物。
Biomark Res. 2016 Mar 3;4:6. doi: 10.1186/s40364-016-0060-9. eCollection 2016.
4
Progression of a hepatosplenic gamma delta T-cell leukemia/lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach.18例肝脾γδT细胞白血病/淋巴瘤接受hyperCVAD/MTX和阿糖胞苷治疗后的病情进展：文献综述及我们机构的治疗方法
Clin Case Rep. 2015 Nov 23;4(1):67-71. doi: 10.1002/ccr3.453. eCollection 2016 Jan.
5
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.CD20阴性弥漫性大B细胞淋巴瘤：695例病例的综合分析
Tumour Biol. 2016 Mar;37(3):3619-37. doi: 10.1007/s13277-015-4205-5. Epub 2015 Oct 12.
6
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.BCL2拮抗剂ABT-199可触发细胞凋亡，并增强依鲁替尼和idelalisib对CXCR4野生型和CXCR4 WHIM突变型华氏巨球蛋白血症细胞的细胞毒性作用。
Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278. Epub 2015 Jan 12.
7
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.剂量调整的EPOCH联合利妥昔单抗（DA-EPOCH-R）方案用于初治预后不良的大B细胞淋巴瘤患者的长期随访。西班牙PETHEMA研究组开展的一项II期研究。
Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.
8
CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis.以乳酸酸中毒为表现的CD20阴性弥漫性大B细胞淋巴瘤
Am J Hematol. 2015 Mar;90(3):E49-50. doi: 10.1002/ajh.23904.
9
CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.HIV 阴性患者中 CD20 阴性新发弥漫性大 B 细胞淋巴瘤：单中心匹配病例对照分析。
J Transl Med. 2012 May 3;10:84. doi: 10.1186/1479-5876-10-84.
10
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.CODOX-M/IVAC方案治疗原发性难治性或复发性高级别非霍奇金淋巴瘤的一项初步研究。苏格兰和纽卡斯尔淋巴瘤研究小组的研究。
Haematologica. 2003 Dec;88(12):1366-71.